The government of the Buenos Aires province recently signed a contract with the Indian laboratory Bharat Biotech with the goal of obtaining ten million vaccines Covaxin and with the possibility of adding five million more.
The governor Axel Kicillof He specified in a press conference that although the vaccine still has to be approved by the Anmat so that it can be imported, the doses that are acquired will be offered to the National Government “so that they can be distributed among all Argentine provinces.”
This compromise agreement for the acquisition of the Covaxin vaccine would allow more people to be immunized by the middle of the year than estimated so far with the successive arrivals of Sputnik V, Sinopharm, Astrazeneca and those provided by the Covax mechanism.
The details of the Covaxin vaccine
The Covaxin vaccine, produced by Indian pharmaceutical company Bharat Biotech, was approved in January this year after demonstrating a 81 percent effective after successfully passing the studies of step 3.
It is the most widely used vaccine in the Indian immunization campaign, which placed this country among the first with the highest percentage of vaccinated population. Despite this, the laboratory that manufactured it was criticized for having launched it on the market before the final phase 3 tests, that is, before it was formally authorized. But then those studies were completed and the endorsement was obtained.
The president of Bharat Biotech, Krishna Ella, assured that Covaxin “not only demonstrates a trend towards a high clinical efficacy against the virus but also a significant immunogenicity (ability of an antigen to induce an immune response) against the variants that emerge unexpectedly” .
“Serious adverse effects, requiring medical assistance, were at very low levels, balanced between the vaccine and placebo groups,” Ella added.
Last February, when the inoculation was extended to people over 60 and over 45 with serious pathologies, Prime Minister Narendra Modi received a dose to demonstrate his confidence in the drug.
In that same month, the Brazilian government decided to buy 20 million doses of Covaxin, whose first batch of 8 million arrived in March. However, the Sanitary Surveillance Agency (Anvisa) affirmed that it did not receive a request for an emergency or definitive authorization.
Due to this, Covaxin has not yet been approved in Brazil and the Brazilian health authorities continue to analyze the phase 3 efficacy and safety trials, while anticipating that they will begin to apply it when these studies have finished.
In Argentina, the first analyzes made by experts gave satisfactory results. The Minister of Health of the province of Buenos Aires, Daniel Gollan, pointed out that Covaxin “has been giving very good results” and that “it is a vaccine with inactivated virus, similar to Sinovivac or Sinofarm”, with the advantage that “It is very stable and remains at high temperatures for many days.”
Gollan announced that the results of the clinical trials will soon be published in The Lancet.